−1.15USD
−14.58 MUSD
12.06 M
About Acurx Pharmaceuticals, Inc.
Sector
CEO
David P. Luci
Headquarters
New York
Website
Employees (FY)
4
Founded
2017
ISIN
US00510M1045
FIGI
BBG01184DNJ4
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ACXP is 2.13 USD — it has increased by 18.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Acurx Pharmaceuticals, Inc. stocks are traded under the ticker ACXP.
Acurx Pharmaceuticals, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
ACXP stock is 18.33% volatile and has beta coefficient of −2.09. Check out the list of the most volatile stocks — is Acurx Pharmaceuticals, Inc. there?
One year price forecast for Acurx Pharmaceuticals, Inc. has a max estimate of 12.00 USD and a min estimate of 10.00 USD.
ACXP earnings for the last quarter are −0.24 USD whereas the estimation was −0.27 USD which accounts for 11.11% surprise. Estimated earnings for the next quarter are −0.25 USD. See more details about Acurx Pharmaceuticals, Inc. earnings.
Yes, you can track Acurx Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
ACXP stock has risen by 15.76% compared to the previous week, the month change is a 10.88% fall, over the last year Acurx Pharmaceuticals, Inc. has showed a 31.51% decrease.
ACXP net income for the last quarter is −5.11 M USD, while the quarter before that showed −3.11 M USD of net income which accounts for −64.19% change. Track more Acurx Pharmaceuticals, Inc. financial stats to get the full picture.
Today Acurx Pharmaceuticals, Inc. has the market capitalization of 30.82 M, it has decreased by 11.98% over the last week.
No, ACXP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ACXP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Acurx Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 4.00 employees. See our rating of the largest employees — is Acurx Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Acurx Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Acurx Pharmaceuticals, Inc. stock shows the sell signal. See more of Acurx Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Acurx Pharmaceuticals, Inc. future price: according to them, ACXP price has a max estimate of 12.00 USD and a min estimate of 10.00 USD. Read a more detailed Acurx Pharmaceuticals, Inc. forecast: see what analysts think of Acurx Pharmaceuticals, Inc. and suggest that you do with its stocks.